Nature Aging study identifies vanadyl sulfate as a senolytic targeting cysteine reactivity

Researchers have identified the dietary supplement vanadyl sulfate as a senolytic that targets altered protein cysteine reactivity to clear senescent cells, improving age-related conditions and extending lifespan in mice.

A study published in Nature Aging by Wu, Yang, Li, and colleagues reports that senescent cells exhibit altered protein cysteine reactivity.

The researchers identified vanadyl sulfate, a dietary supplement, as a senolytic agent that targets this specific biological vulnerability.

Administration of vanadyl sulfate cleared senescent cells, improved age-related physiological conditions, and extended the lifespan of mouse models.

The identification of altered protein cysteine reactivity provides a novel, biophysical target for clearing senescent cells, distinct from established senolytic approaches that target anti-apoptotic pathways.

Using a supplement like vanadyl sulfate as a starting point could simplify early academic validation of this pathway, although therapeutic safety margins and translational efficacy in humans remain unestablished.

The discovery introduces a novel targeting mechanism (cysteine reactivity) to the broader senolytic landscape, potentially informing future drug discovery programs.

Because vanadyl sulfate is already commercially available as a supplement, the publication may stimulate consumer-led interest and off-label usage, similar to previous trends observed with other dietary compounds associated with longevity.

Follow-up preclinical studies evaluating the safety profile and exact therapeutic window of vanadyl sulfate when used specifically for senolytic purposes.

Any potential clinical trial filings evaluating the efficacy of vanadyl sulfate or derivative compounds in humans for age-related indications.